The idea, which is not a stupid one
It is worth starting with what is genuinely interesting here, because the pitch is not nonsense. Almost every treatment for erectile dysfunction manages the symptom: a tablet dilates blood vessels for a few hours, a pump produces an erection now, a ring holds one. None of them changes the underlying tissue. The proposition behind shockwave therapy is different — that pulses of acoustic energy applied to penile tissue trigger a healing response, including angiogenesis, the growth of new blood vessels. If that worked reliably, it would be the first widely available treatment that improved the plumbing rather than working around it.
That is a real research direction with real published studies behind it, and our shockwave therapy page covers where the evidence stands. The short version: some trials show benefit, particularly in men with vasculogenic ED who still respond partially to PDE5 inhibitors; the trials are mostly small, short, and inconsistent in protocol; sham-controlled results are weaker than open-label ones; and durability past a year is poorly established.
The technical problem: focused versus radial
This is the part of the analysis that changes the conclusion, and it is almost never explained to buyers. 'Shockwave' and 'acoustic wave' get used interchangeably in marketing. In physics and in the trials, they are not interchangeable.
| Focused shockwave | Radial pressure wave | |
|---|---|---|
| How it is generated | Electrohydraulic, electromagnetic or piezoelectric, then focused to a point | A projectile striking an applicator, spreading outward from the surface |
| Energy at depth | Concentrated at a defined focal depth | Highest at the skin, falling away rapidly with depth |
| Used in the ED trials | Yes — this is what the published studies used | Largely not |
| Typical setting | Clinic, trained operator, machine costing thousands | Consumer handhelds and physiotherapy massage devices |
The consequence is straightforward. If the mechanism depends on delivering a particular energy density to tissue at depth, and a device delivers something weaker that dissipates near the surface, then the trials of the first device tell you very little about the second. The marketing bridges that gap by talking about shockwave therapy in general and then selling you a handheld. The evidence does not bridge it.
What the FDA has and has not said
This matters beyond pedantry. Clearance for an indication is the mechanism by which somebody outside the company checks that the claimed benefit is supported. Without it, the only quality control on the claim is the company making it, and the FTC's guidance on health claims is the only backstop. When a device is sold for a use it has not been authorised for, you are the trial.
It also affects what happens if something goes wrong. There is no prescriber, no assessment of whether you are a candidate, and no clinician who knows you have been doing this. Men with Peyronie's disease, penile implants, bleeding disorders, active infection, or anyone on anticoagulants should not be self-administering acoustic energy without medical advice, and a website that sells to anyone with a card is not going to establish which of those apply to you.
Where the $879 could go instead
Opportunity cost is the strongest argument here, stronger than any objection to the device itself. Money spent on an investigational home treatment is money not spent on things with settled evidence — and in this field, the proven options are cheap.
| Instead | Roughly what it costs | Evidence |
|---|---|---|
| Generic tadalafil, daily, for years | $20–$40 for 90 days | Strong — guideline first-line |
| Medical-grade vacuum device | $100–$500 one-off | Strong — around 90% achieve a usable erection |
| A urology consultation and workup | $150–$400 without insurance | Finds the cause instead of guessing at it |
| Sex therapy, several sessions | $100–$250 per session | Strong for psychogenic and mixed ED |
| Pelvic floor physiotherapy | $80–$200 per session, often a handful | Randomised trial evidence, particularly for venous leak |
The narrow case for buying one anyway
We are not going to pretend nobody should ever buy this. There is a narrow set of circumstances where it is a defensible choice, and it is worth stating them plainly rather than leaving the review as a wall of objections.
- You have vasculogenic ED — the blood-flow kind — confirmed by a clinician, rather than post-surgical nerve damage or a hormonal cause. That is the only group the published benefit has been seen in.
- You have already tried PDE5 inhibitors and either they help partially or you cannot take them.
- You understand you are buying something investigational, and you are not going to conclude the world is against you when it does not work.
- $879 is money you can lose. Not money you are moving from something else you need.
- You have told a clinician you are doing it, so it is on your record if a problem arises.
Reviewed individually
The Phoenix sells several different things, and they are not equivalent — some are FDA-approved generics, some are brand-name originals, and some are compounded formulations that have not been through FDA review. Each is reviewed separately, with the retail price of the same molecule shown alongside.
Frequently asked questions
Is The Phoenix FDA approved?
Does at-home shockwave therapy work for ED?
How much does The Phoenix cost?
Is it cheaper than in-office shockwave therapy?
Who should not use it?
Will it fix ED permanently?
What should I do instead?
What this is based on
We link to primary sources — clinical guidelines, regulator publications and peer-reviewed research — wherever possible. Links open on third-party sites we do not control.
- [01]American Urological Association. Erectile Dysfunction: AUA Guideline (2018).
- [02]U.S. Food and Drug Administration. Device registration and listing — what it does and does not mean.
- [03]National Library of Medicine. ClinicalTrials.gov — find studies you can join.
- [04]National Library of Medicine. PubMed — search the primary literature.
- [05]Federal Trade Commission. Health Products Compliance Guidance.